65,437 trials
Chronic Allergic Conjunctivitis
Primary: Ocular Itching — 1.80; 2.58; 1.72; 2.70 units on a scale (0 -4)
Chronic Obstructive Pulmonary Disease
Primary: Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores (Quality of Life and Symptoms) Changes Within a Treatment Period and Comparison Between the Two Groups…
Chronic Idiopathic Constipation
Primary: Number of Patients With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 241; 14 Patients
Aortic Valve Stenosis · Aortic Valve Calcification · Aortic Valve Disease
Primary: Clinical Procedural Success — 9 participants
Prostate Cancer
Primary: Percentage of Patients Completing at Least 3 Months of Therapy With a PSA Below Baseline. — 42.9 Percentage of Participants
Psoriasis Vulgaris
Primary: Treatment Success According to IGA — 53.3; 4.8 percentage of subjects — p=<0.001
Cystic Fibrosis
Primary: Rate of Protocol-defined Exacerbations (PDE) From Baseline Through Week 24 — 1.309; 1.762 PDEs per participant year — p=0.25
Myocardial Infarction (MI)
Primary: Number of Occurrences of Cardio-vascular Events — 4; 3; 4 events
Kidney Transplantation
Primary: Response to Bortezomib Monotherapy — 0; 0; 0; 1 participants
Influenza
Primary: Percent MMID — 0; 0; 20; 47 percentage of participants
Smoking Cessation
Primary: Number of Participants Who Stopped Smoking by 12 Month Post Treatment — 31; 41 participants
Hemophilia B
Primary: Change in Frequency of Spontaneous Bleeding Events Between On-demand and Prophylaxis Treatments (Annualized) — 15.43; 0.00 bleeds/year/subject — p=<0.0001
Actinic Keratosis
Primary: Number of Participants With Complete Clearance of AKs 8 Weeks After Randomisation — 43; 9; 25; 5 participants — p=0.001
Cancer
Primary: To Determine the Safety and Tolerability of a Modified Low Carbohydrate Diet in People With Advanced Cancer Across Different Tumor Types. — 11 participants
Myelodysplastic Syndromes
Primary: Number of Participants Who Experienced an Adverse Event — 6 participants